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Conditioning to Injection Procedures and 
Repeated Testing Increase SCH 23390-Induced 
Catalepsy in Mice
 
Cibele Cristina Chinen, B.Sc., and Roberto Frussa-Filho, Ph.D.
 
The cataleptic behavior induced by the dopamine D
 
1
 
 
antagonist SCH 23390 (SCH) has proven to be a useful 
assay for investigating the sensitivity of D
 
1
 
-like dopamine 
receptor-mediated effects during chronic drug 
administration. A fundamental flaw in most of these studies 
may be the involvement of the “repeated measures effect,” a 
behavioral phenomenon well demonstrated for neuroleptic-
induced catalepsy but not yet investigated for dopamine D
 
1
 
 
antagonists. In this study, mice exposed for various sessions 
to the bar test presented a strong sensitization to the 
cataleptic behavior induced by repeated SCH treatment. 
Conversely, single tested animals exhibited a trend toward 
decreased catalepsy after repeated SCH treatment, which 
was in line with the development of a D
 
1
 
-like dopamine 
receptor supersensitivity suggested by an increase in SKF 
38393-induced grooming behavior. Surprisingly, a 
challenge intraperitoneal saline injection increased the 
cataleptic behavior of single tested mice after long-term 
SCH treatment. This “injection-conditioned catalepsy” was 
also observed after repeated treatment with the dopamine D
 
2
 
 
antagonists, haloperidol and metoclopramide. While these 
findings seem to explain some important contradictory data 
in the literature, they provide a new and simple animal 
model of the placebo effect. 
 
[Neuropsychopharmacology 
21:670–678, 1999]
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The ability of chronic neuroleptic treatment to produce
increasing or decreasing degrees of both Parkinsonism
in humans (see Hansen and Hoffman 1997) and cata-
lepsy in laboratory animals (Barnes et al. 1990) over
time remains controversial. Specifically, concerning the
evolution of catalepsy during chronic haloperidol treat-
ment, tolerance (Asper et al. 1973; Ezrin-Waters and
Seeman 1977; Campbell and Baldessarini 1981), sensiti-
zation (Antelman et al. 1986; Kinon and Kane 1989;
Barnes et al. 1990), or no effects (György et al. 1969;
Moller Nielsen et al. 1974; Frussa-Filho et al. 1992) have
been reported. Although the patterns of change in cata-
lepsy responses to chronic neuroleptic treatment are in-
fluenced by multiple determinants (Barnes et al. 1990),
two specific biological mechanisms seem to be of partic-
ular importance in determining the development of tol-
erance or sensitization: dopamine receptor supersensi-
tivity (Ezrin-Waters and Seeman 1977; Hoffman and
Beninger 1988) and a learning process due to repeated
testing in the catalepsy apparatus (Iwata et al. 1989;
Ferré et al. 1990), respectively. In regards to the learning
process, both repeated measures in a single session af-
ter acute haloperidol administration (Stanley and Glick
1976; Hillegaart et al. 1987 and repeated observation
sessions during chronic haloperidol treatment (Barnes
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et al. 1990) have been reported to markedly enhance the
cataleptic behavior presented by rodents.
For many years, dopamine D
 
2
 
-like receptors were
implicated as the only site mediating the cataleptic be-
havior of neuroleptics (Seeman 1980). However, in
1984, Christensen et al. (1984) first reported the catalep-
togenic properties of SCH 23390, a selective antagonist
of D
 
1
 
-like dopamine receptors (Hyttel 1983). Thus, be-
sides providing a functional correlate of dopamine D
 
1
 
receptor antagonism (Mizuki et al. 1996), SCH 23390-
induced catalepsy has proven to be a useful assay for
investigating the functional interactions between D
 
1
 
-
and D
 
2
 
-like dopamine receptors (see Klemm 1993). Cat-
alepsy has also been used to investigate the sensitivity
of D
 
1
 
-like dopamine receptor-mediated effects during
chronic drug administration. In two landmark investi-
gations, Hess et al. (1986, 1988) reported that although
chronic treatment of rats with SCH 23390 resulted in an
increase in D
 
1
 
-like striatal dopamine receptors as well
as in spontaneous locomotion and D
 
1
 
-like and D
 
2
 
-like
dopamine agonist-induced stereotypy, no tolerance to
the cataleptic effect of the drug was observed. Similarly,
Lappalainen et al. (1989) reported that chronic treat-
ment of rats with a low dose regimen (0.1 mg/kg) of
SCH 23390 did not lead to the development of tolerance
to the cataleptic response in the bar test. In addition, al-
though the cataleptic effect of a higher dose regimen
(0.5 mg/kg) of SCH 23390 was significantly reduced af-
ter a 6-day treatment, this subacute tolerance was grad-
ually reversed and was no longer significant after 12
and 18 days. Different functional mechanisms were
proposed to explain the lack of tolerance to SCH 23390-
induced catalepsy in these three studies. However, a
possible involvement of a learning process due to re-
peated testing was not experimentally considered by
Hess et al. (1986, 1988) or Lappalainen et al. (1989) de-
spite the fact that the animals were repeatedly tested for
catalepsy during the course of the experiments.
In order to investigate this possibility, the initial aim
of the present study was to examine the effects of
chronic SCH 23390 treatment on the cataleptic behavior
of mice tested repeatedly over time or only once on the
horizontal bar. To functionally evaluate the sensitivity
of D
 
1
 
-like dopamine receptors after the chronic SCH
23390 treatment, the effects of a challenge injection of
the D
 
1
 
-like dopamine agonist SKF 38393 on grooming
behavior was also quantified. The effect of repeated
measures on SCH 23390-induced catalepsy should also
be of interest in light of the hypothesis that D
 
1
 
-like
dopamine receptors are the final target from which
dopamine elicits rewarding effects (see Miller et al.
1990). Indeed, according to these authors, a “repeated
measures effect” on catalepsy behavior should not be
expected after treatment with dopamine D
 
1
 
 antagonists
because the reward signal upon which the conditioning
depends (stimulation of dopamine D
 
1
 
 receptors) is
abolished. Interestingly, the present data show that
mice exposed for various sessions to the bar test pre-
sented a strong sensitization to the cataleptic behavior
induced by repeated treatment with SCH 23390,
whereas a trend toward tolerance was observed in mice
submitted to a single test but identically treated with
the dopamine D
 
1
 
 antagonist. More important, our data
clearly show that mice long-term treated with SCH
23390 and single tested developed “an injection-condi-
tioned catalepsy,” i.e., an increase in the cataleptic be-
havior induced by a saline injection. Finally, we demon-
strate that this new and provocative phenomenon is
also observed after long-term treatment with a selective
or a preferential D
 
2
 
-like dopamine receptor antagonist.
 
MATERIALS AND METHODS
General Methods
 
Subjects.  
 
Male EPM-M1 mice from our own colony,
weighing 30–40 g were used. The animals arrived at the
experimental laboratory at least 10 days before the be-
ginning of the experiments. They were housed in
polypropylene cages (32 
 
3
 
 40 
 
3
 
 15 cm), 15 per cage,
with access to food and water 
 
ad libitum.
 
 Light/dark cy-
cle (lights on at 6:00 A.M., off at 6:00 P.M.) and tempera-
ture (22
 
8
 
C) were kept constant. All experiments took
place between 11:00 A.M. and 2:00 P.M. The animals
were maintained and used in accordance to the guide-
lines of the Committee on Care and Use of Experimen-
tal Animal Resources, School of Veterinary Medicine
and Animal Science of the University of São Paulo,
Brazil.
 
Test Agents.  
 
R(
 
1
 
)-7chloro-8-hydroxy-3-methyl-1-
phenyl- 2,3,4,5-tetrahydro-1H-3-benzazepine (SCH 23390,
RBI); R(
 
1
 
)-1-phenyl-2,3,4,5,-tetrahydro-1H-3benzazepine-
7,8 diol (SKF 38393, RBI), metoclopramide hydrochlo-
ride (Lepetit S/A), and haloperidol (Haldol injectable
solution 5mg mL
 
2
 
1
 
, Johnson and Johnson) were used.
The drugs were freshly diluted in distilled water and
were given intraperitoneally (except for SKF 38393,
which was given subcutaneously) in volumes not
greater than 10 ml/kg body weight. Saline was used as
control solution. SCH 23390, SKF 38393, and metoclo-
pramide doses were calculated as the salt. Haloperidol
was calculated as the free base.
 
Catalepsy Testing.  
 
Catalepsy responses were mea-
sured by means of the bar method. Mice were gently re-
moved from their home cage by their tail and their fore-
paws were placed over a glass horizontal bar, 0.5 cm in
diameter and 30 cm long, which was fixed at a height of
4 cm above the working surface. As proposed by sev-
eral authors (Barnes et al. 1990; Dijk et al. 1991; Rocha et
al. 1997), to perform one catalepsy determination at one
time point, the animal was given three trials. The sum
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(or the average) of these trials make possible to de-
crease the stress-induced data variability produced by
the handling procedure as compared to a single trial
per determination. In each trial, the duration of cata-
lepsy was timed from the instant the animals were
firstly placed over the bar to the instant they removed
both forepaws from the bar or climbed over the bar
with the hind limbs. The determination of catalepsy
was performed 15 and 35 min after drug administration
and the animals were returned to their cages between
determinations. A preset cut-off of 19 minutes was used
in each determination. This long cut-off time was em-
ployed because short cut-off values have been sug-
gested to obscure modifications in the evolution of the
cataleptic behavior during chronic drug treatment regi-
men (Sanberg et al. 1988). As suggested by previous
studies (Undie and Friedman 1988; Lipska et al. 1995),
the total amount of time that the mice remained in cata-
leptic posture (i.e., the sum of the catalepsy durations of
the six trials performed) was calculated to give the cu-
mulative catalepsy time for each animal. The cumula-
tive catalepsy time (in seconds) was then transformed
to logarithmic values (ln) to normalize the data as pro-
posed by Ferré et al. (1990) and this value was used to
perform statistical analysis.
 
Grooming Testing.  
 
Grooming behavior in response to
the dopamine D
 
1
 
 agonist SKF 38393 was selected as a
measure of dopamine D
 
1
 
 receptor function, since it ap-
pears to be specific for dopamine D
 
1
 
 receptor stimula-
tion (Molloy and Waddington 1984; Parashos et al.
1990). Immediately after a subcutaneous injection of 10
mg/kg SKF 38393, mice were individually observed for
grooming behavior in wire mesh cages (16 
 
3
 
 30 
 
3
 
 19
cm) free of water and food. The duration of this behav-
ior was measured for 1 min at 5 min intervals for 60
min. The sum of the durations (in seconds) of grooming
recorded for each animal was used to perform statisti-
cal analysis.
 
Procedures
 
Experiment 1: Evolution of SCH 23390-Induced Cata-
lepsy in Mice Submitted to Repeated Testing on the
Horizontal Bar.  
 
Twenty-five mice were allocated
randomly to two groups which received intraperito-
neally (i.p.) 0.1 mg/kg SCH 23390 (
 
n
 
 
 
5
 
 13) or saline
(
 
n
 
 
 
5
 
 12) once a day for 15 days. On days 1, 5, 10, and 15,
the animals of both groups were observed for catalepsy
behavior 15 min after the respective daily injection.
Three days after the last SCH 23390 or saline injection
(day 18), animals of both groups were injected subcuta-
neously with 10 mg/kg SKF 38393 for grooming behav-
ior quantification. SKF 38393-induced grooming behav-
ior was measured three days after withdrawal from
SCH 23390 treatment because this time point has been
 
reported to better display behavioral supersensitivity
after withdrawal from chronic administration of
dopamine receptor blockers (Frussa-Filho and Palermo-
Neto 1988, 1990; Vital et al. 1995).
 
Experiment 2: Effects of Long-Term SCH 23390 Admin-
istration on the Cataleptic Behavior of Mice Submitted
to a Single Testing on the Horizontal Bar.  
 
Eighty mice
were divided into five equal groups (
 
n
 
5
 
16) which re-
ceived 0.1 mg/kg, i.p. SCH 23390 (SCH
 
fi
 
) or saline
(SAL
 
fi
 
) once a day for 14 days. On the 15
 
th
 
 day, ani-
mals of some groups received a challenge injection of
SCH 23390 (
 
fi
 
SCH) or saline (
 
fi
 
SAL) whereas mice of
one group were not injected (
 
fi
 
NI). Thus, the five
groups of animals were as follows: SAL
 
fi
 
SAL, SAL
 
fi
 
SCH, SCH
 
fi
 
SCH, SCH
 
fi
 
SAL, and SCH
 
fi
 
NI. Fifteen
minutes after their respective challenge injection, the
animals were observed for the first time for catalepsy
quantification. The catalepsy recording of the animals
of the SCH
 
fi
 
NI group was alternated with that of mice
of the other four groups.
 
Experiment 3: Conditioned Catalepsy after Long-Term
Administration of SCH 23390, Metoclopramide or Halo-
peridol.  
 
One hundred mice were allocated randomly
to eight groups of 12–13 animals each, which received
0.1 mg/kg, i.p. SCH 23390 (SCH
 
fi
 
), 30 mg/kg metoclo-
pramide (MET
 
fi
 
), 1.0 mg/kg haloperidol (HAL
 
fi
 
), or
saline (SAL
 
fi
 
) once a day for 14 days. On the 15
 
th
 
 day,
the animals received a challenge injection of saline
(
 
fi
 
SAL) or were not injected (
 
fi
 
NI). Thus, the eight
groups were as follows: SAL
 
fi
 
SAL, SAL
 
fi
 
NI, SCH
 
fi
 
SAL, SCH
 
fi
 
NI, MET
 
fi
 
SAL, MET
 
fi
 
NI, HAL
 
fi
 
SAL,
and HAL
 
fi
 
NI. Fifteen minutes after the saline chal-
lenge injection, the animals were observed for the first
time for catalepsy quantification. The catalepsy record-
ing of the animals of the NI groups was alternated with
that of the mice challenged with saline.
Each animal was used in only one experiment and in
all the experiments the observer was blind to the iden-
tity of the animal. In the three experiments, mice were
long-term treated, challenged and observed for cata-
lepsy in different rooms.
 
Statistics
 
For experiment 1, differences in cataleptic behavior were
evaluated by 2 
 
3
 
 4 (Treatment 
 
3
 
 Sessions) analysis of
variance (ANOVA) with repeated measures. For experi-
ment 2, results were compared by one-way ANOVA
and, for experiment 3, 4 
 
3
 
 2 (Pretreatment 
 
3
 
 Challenge)
ANOVA was used. When ANOVA revealed significant
interactions, post hoc comparisons were made by the
Student Newman-Keuls test (except for group effects
comparison in experiment 1, where the Student’s 
 
t
 
-test
was used). A conventional Student’s 
 
t
 
-test was also used
to compare grooming data of experiment 1.
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RESULTS
Experiment 1: Evolution of SCH 23390-Induced 
Catalepsy in Mice Submitted to Repeated Testing on 
the Horizontal Bar
 
The data obtained in experiment 1, designed to assess
the influence of repeated testing on the catalepsy re-
sponse of mice long-term treated with saline or SCH
23390, is shown in Figure 1. Two-way ANOVA with re-
peated measures revealed significant treatment [F(1,23) 
 
5
 
294.56; 
 
p
 
 
 
,
 
 .001], session [F(3,69) 
 
5
 
 36.30; 
 
p
 
 
 
,
 
 .001] and
treatment 
 
3
 
 session interaction [F(3,69) 
 
5
 
 6.35; 
 
p
 
 
 
5
 
.001] effects. Indeed, in relation to mice long-term
treated with saline, post hoc analysis revealed that ani-
mals treated with SCH 23390 presented a higher cata-
lepsy duration in all the observation sessions. In both
groups, catalepsy duration significantly increased over
time, but the increase in cataleptic behavior induced by
repeated testing was observed earlier in mice treated
with SCH 23390 when compared to mice receiving sa-
line. Whereas the catalepsy duration presented on days
5, 10, and 15 by animals treated with SCH 23390 was
significantly higher than that presented on day 1, the
catalepsy response presented only on days 10 and 15 by
mice receiving saline was significantly higher than that
recorded on day 1.
Besides the increase in cataleptic behavior after re-
peated testing, the mice treated chronically with SCH
23390 also showed an increase in the grooming behav-
ior induced by SKF 38393, three days after drug with-
drawal [T(23) 
 
5 2.69, p , .05] (Table 1).
Experiment 2: Effects of Long-Term SCH 23390 
Administration on the Cataleptic Behavior of Mice 
Submitted to a Single Testing on the Horizontal Bar
As can be seen in Figure 2, in contrast to the results of
experiment 1, no sensitization to the catalepsy response
was observed when mice submitted to an identical
treatment with SCH 23390 were tested for catalepsy on
day 15 only. Rather, the comparison of the catalepsy
duration presented by mice of the SCH fi SCH group vs.
that of the SAL fi SCH group showed a strong trend to-
ward decreased catalepsy. As expected, these two
groups presented a catalepsy response significantly
higher than that of the SAL fi SAL, SCH fi SAL and
SCH fi NI groups [F(4,75) 5 16.42; p , .001]. Unexpect-
edly, however, mice of the SCH fi SAL group showed
significantly higher values of catalepsy when compared
to the SAL fi SAL as well as to the SCH fi NI group,
which did not differ from each other.
Experiment 3: Conditioned Catalepsy after
Long-Term Administration of SCH 23390, 
Metoclopramide or Haloperidol
Figure 3 shows the data obtained in experiment 3, de-
signed to replicate the “injection-induced” catalepsy
observed after long-term SCH 23390 treatment in exper-
iment 2 and to verify if such a phenomenon would also
be observed after repeated administration of the selec-
tive and preferential dopamine D2 antagonists metoclo-
Figure 1. Evolution of SCH 23390-induced cat-
alepsy in mice submitted to repeated testing on
the horizontal bar. Animals were treated daily
with injections of 0.1 mg/kg SCH 23390 (SCH)
or saline (SAL) for 15 days and were tested for
catalepsy on days 1, 5, 10, and 15 after the begin-
ning of treatment. Data are expressed as means 6
SEM for 12–13 animals in each group. * p , .05
compared to mice treated with saline (two-way
ANOVA with repeated measures and Student’s
t-test). w p , .05 compared to day 1 data for the
respective treatment (two-way ANOVA with
repeated measures and Student Newman-Keuls
test).
Table 1. Effect of withdrawal from long-term treatment 
with SCH 23390 on SKF 38393-induced grooming behavior 
in mice
Long-term treatment Challenge Grooming duration (sec)
Saline SKF 38393 215.2 6 4.1
SCH 23390 SKF 38393 234.7 6 5.8a
Mice were long-term treated with SCH 23390 or saline as described in
Figure 1. Seventy-two hours after withdrawal from their respective treat-
ments, all the animals received 10 mg/kg SKF 38393 s.c. and grooming
behavior was quantified. Data are expressed as the mean 6 SEM for 12-
13 animals in each group.
a p , .05 compared to mice treated with saline (Student’s t -test).
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pramide and haloperidol, respectively. Two-way
ANOVA revealed significant pretreatment [F(3.92) 5
26.80; p , .001] and challenge [F(1,92) 5 13.99; p 5 .002]
effects. The pretreatment 3 challenge interaction effect
was not significant [F(3,92) 5 1.206; p 5 .312]. In agree-
ment with the data of experiment 2, post hoc analysis
revealed that mice of the SCH fi SAL group spent signif-
icantly more time in catalepsy than animals of the SCH
fi NI and SAL fi SAL groups, which did not differ from
each other. This “injection-conditioned” catalepsy was
also observed after long-term haloperidol treatment. In-
deed, although the duration of catalepsy presented by
mice of the HAL fi NI group was significantly higher
than that of the SAL fi SAL group, it was significantly
lower than that of the HAL fi SAL group. Although no
significant difference in catalepsy duration was ob-
served between the MET fi SAL and MET fi NI groups,
an “injection-conditioned” catalepsy after metoclopra-
mide treatment was suggested by the fact that, unlike
the MET fi NI group, the catalepsy duration presented
by mice of the MET fi SAL group was significantly
higher than those of the SAL fi SAL or SAL fi NI groups.
Finally, it is important to note that no difference in cata-
lepsy duration was observed between the SAL fi SAL
and SAL fi NI groups.
DISCUSSION
The major findings of the present investigation were
that: 1) mice treated daily with SCH 23390 for 15 days
and submitted to repeated testing on the horizontal bar
presented a strong increase (sensitization) in cataleptic
behavior over time; 2) although it developed more
slowly and was much smaller in magnitude, sensitiza-
tion was also observed in the multiple test long-term sa-
Figure 2. Effects of long-term SCH 23390
administration on the cataleptic behavior of
mice submitted to a single test on the horizon-
tal bar. Animals were treated daily with i.p.
injections of 0.1 mg/kg SCH 23390 (SCHfi ) or
saline (SALfi ) for 14 days and tested on day 15
after challenge i.p. injection of SCH 23390
(fi SCH) or saline (fi SAL). A group of SCH
23390-pretreated animals were not injected
(fi NI) on the test day. Data are expressed as
the mean 6 SEM for 16 animals in each group.
*p , .05 compared to mice of the SALfi SAL
and SCHfi NI groups (one-way ANOVA and
Student Newman-Keuls test).
Figure 3. Injection-conditioned catalepsy after
long-term administration of SCH 23390, metoclo-
pramide or haloperidol. Animals were treated
daily with i.p. injections of 0.1 mg/kg SCH 23390
(SCHfi ), 30 mg/kg metoclopramide (METfi ), 1.0
mg/kg haloperidol (HALfi ), or saline (SALfi )
for 14 days and tested on day 15 after a challenge
injection of saline (fi SAL) or after receiving no
injection (fi NI). Data are expressed as the mean 6
SEM for 12–13 animals in each group. *p , .05
compared to mice of the SALfi SAL and SALfi NI
groups. w p , .05 compared to the respective
“non-injected” group (submitted to the same pre-
treatment). Two-way ANOVA and Student New-
man-Keuls test.
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line-treated group; 3) the sensitization to the cataleptic
behavior in the multiple test SCH 23390-treated group
was observed in spite of the development of a D1-like
dopamine receptor supersensitivity which was sug-
gested by an increase in SKF 38393-induced grooming
behavior; 4) mice treated daily with SCH 23390 for 15
days and submitted to a single test showed a trend to-
ward decreased catalepsy; 5) these animals also devel-
oped an injection-conditioned cataleptic behavior which
was also verified after both metoclopramide and halo-
peridol long-term treatments.
The marked effect of repeated testing described in
experiment 1 seems to clarify some controversial data
in the literature. For example, as mentioned before,
Hess et al. (1986, 1988) did not observe tolerance to the
cataleptic behavior of rats treated with SCH 23390 for
21 days in spite of verifying an increase in D1-like stri-
atal dopamine receptors as well as in spontaneous loco-
motion and in the stereotyped behavior induced by
D1-like or D2-like dopamine receptor agonists. Since in
both studies (Hess et al. 1986, 1988) the rats were re-
peatedly tested for catalepsy during the course of the
experiments, the absence of the expected tolerance
might have been due to repeated testing. On the other
hand, in contrast to the present data, Hess et al. (1986,
1988) did not observe sensitization to the cataleptic be-
havior of rats repeatedly treated with SCH 23390. In-
deed, the sensitization phenomenon might be expected
in this context since in some experiments rats were
tested 6 times for catalepsy during the course of the
chronic SCH 23390 treatment. However, a likely expla-
nation for the absence of sensitization in these experi-
ments is a ceiling effect due to the short cut-off time
(120 sec) employed by Hess et al. (1986, 1988).
The increase in SCH 23390-induced catalepsy pro-
duced by repeated testing, verified herein, might also
explain why the initial tolerance to the cataleptic behav-
ior induced by SCH 23390 was gradually reversed and
no longer significant in the experiment performed by
Lappalainen et al. (1989).
As with mice receiving chronic administration of
SCH 23390, mice treated chronically with saline and
tested repeatedly on the horizontal bar demonstrated
significantly higher catalepsy over time. The fact that
drug-free or placebo-treated mice and rats, when
placed repeatedly on a bar with an imposed posture,
“learn” to maintain, even during long periods of time,
such posture has been previously reported in some
studies (Sanberg et al. 1988; Brown and Handley 1980;
Amir et al. 1981; Ferré et al. 1990). According to Ferré et
al. (1990), the most probable cause of this repeated test-
ing effect is the animal’s avoidance of manipulation
when both forepaws touch the floor, being well-known
that handling is a stressor (Axelrod and Reisine 1984).
Consequently, the animal would be forced into an ab-
normal posture and then trained to maintain that pos-
ture. In the present study, the increase in cataleptic be-
havior induced by repeated testing was observed later
in mice treated with saline when compared to mice re-
ceiving SCH 23390. Interestingly, some studies have re-
ported a repeated testing effect for the catalepsy bar test
in haloperidol-treated mice or rats but not in animals
receiving saline (Stanley and Glick 1976; Iwata et al.
1989; Barnes et al. 1990). Thus, one might be led to sus-
pect that a pharmacological component of cataleptic be-
havior would be able to potentiate a learning compo-
nent of this behavior. In contrast, Ferré et al. (1990)
reported that 48 hours after haloperidol or saline ad-
ministration and testing, a second test on the horizontal
bar without any treatment revealed a significantly
longer duration of catalepsy in the previously saline-
treated animals than in the previously haloperidol-
treated ones. Concerning our results, we considered the
possibility that in addition to a repeated testing effect
an injection conditioning phenomenon might have
potentiated the catalepsy behavior of mice treated
chronically with SCH 23390. To test this hypothesis, a
saline-challenged group and a non-challenged group
were included in experiment 2, in which the effects of
long-term treatment with SCH 23390 were evaluated in
mice single tested for catalepsy.
In contrast to mice treated chronically with SCH
23390 and tested repeatedly for catalepsy, mice submit-
ted to an identical treatment with the dopamine D1 re-
ceptor antagonist, but tested for catalepsy on day 15
only, presented a strong trend toward decreased cata-
lepsy. This effect was probably related to the develop-
ment of a D1-like dopamine receptor supersensitivity
after long-term SCH 23390, which has been demon-
strated in binding studies (Creese and Chen 1985; Hess
et al. 1986, 1988) and was behaviorally suggested earlier
(Parashos et al. 1990) and in the present study by an in-
crease in SKF 38393-induced grooming.
The longer catalepsy duration presented by mice
treated chronically with SCH 23390 and challenged
with saline (group SCH fi SAL) compared to mice sub-
mitted to an identical long-term treatment with SCH
23390 but not challenged with any injection (group
SCH fi NI) as well as compared to mice chronically
treated and challenged with saline (group SAL fi SAL),
strongly suggests the development of a drug injection-
conditioning phenomenon, which is, perhaps, the most
striking finding of the present study. Thus, the intero-
ceptive cues and/or the akinesia induced by SCH 23390
would be themselves sufficiently distinct stimuli to be
conditioned to the injection procedure, thereby calling
forth an enhanced response following a subsequent sa-
line injection. In other words, the phenomenon would
be a classical conditioned response in which SCH 23390
(unconditioned stimulus, UCS) was associated with
previously neutral stimulus, i.e., the injection proce-
dure (conditioned stimulus, CS) for 14 times, producing
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akinesia (unconditioned response). On day 15, saline
was substituted for SCH 23390 and the conditioned
stimulus (injection procedure) alone would induce aki-
nesia (conditioned response), thereby increasing the
duration of the cataleptic behavior. This conditioned re-
sponse could explain why, in experiment 1, the increase
in the cataleptic behavior induced by repeated testing
was observed earlier in mice treated with SCH 23390
than in mice receiving saline. It could also explain why,
in experiment 2, only a trend toward decreased cata-
lepsy (but not a significant effect) was observed after
long-term SCH 23390 administration in mice single
tested for catalepsy (group SCH fi SCH vs group
SAL fi SCH).
The aims of experiment 3 were twofold: first to repli-
cate the conditioned cataleptic response observed after
long-term treatment with SCH 23390; second, to verify
if such a conditioned response would also be induced
after repeated administration of the selective or the
preferential D2-like dopamine antagonists metoclopra-
mide and haloperidol, respectively. In this respect,
whereas a challenge injection of saline did not modify
the catalepsy duration presented by mice chronically
treated with saline, it increased significantly the cata-
leptic behavior of mice treated chronically with the
three dopamine receptor antagonists. Interestingly, the
duration of catalepsy behavior exhibited by mice
treated with haloperidol and not challenged with saline
(group HAL fi NI) was significantly longer than the cat-
aleptic behavior presented by mice treated chronically
with saline (groups SAL fi SAL and SAL fi NI), which
was probably due to residual levels of the neuroleptic.
If this is the case, the present data suggest that the con-
ditioned catalepsy can potentiate the unconditioned
one, further supporting the possibility that the repeated
testing effect was higher in the SCH 23390-treated mice
than in the saline-treated animals (experiment 1) be-
cause of an additional effect of the drug injection-condi-
tioned phenomenon.
The fact that, like SCH 23390, repeated treatment
with classical neuroleptics can induce an injection pro-
cedure-conditioned cataleptic behavior may have both
experimental and clinical implications. For example,
this conditioning phenomenon could be related to the
development of sensitization to the cataleptic behavior
of animals treated chronically with neuroleptics but not
submitted to repeated testing (Antelman et al. 1986;
Barnes et al. 1990). Thus, although tolerance is typically
observed with this type of paradigm, a robust injection
procedure-conditioning phenomenon could be related
to these unexpected results. Conditioned catalepsy
could also explain why in a recent study, Ushijima et al.
(1995) verified sensitization to the cataleptic behavior
induced by challenge injections of SCH 23390 or halo-
peridol, but only in mice tested many days after with-
drawal from chronic treatments (when the opposite ef-
fects of a dopamine receptor up regulation on catalepsy
had probably vanished).
From a clinical point of view, since catalepsy is a
well accepted model of neuroleptic-induced Parkin-
sonism, it is tempting to speculate if this drug adminis-
tration-conditioning phenomenon has anything to do
with the controversy concerning the development of
tolerance to neuroleptic-induced Parkinsonism in hu-
mans (see Hansen and Hoffman 1997). Interestingly, it
has already been suggested that psychological factors
related to the placebo effect may play a fundamental
role in the treatment of neuroleptic-induced Parkin-
sonism (St. Jean et al. 1964a,b). However, it should be
noted that one must always be wary of extrapolating
clinical relevance from animal data.
The above concern notwithstanding, the neuroleptic-
induced conditioned catalepsy may provide a new and
simple animal model of the placebo (or, in such a case,
nocebo) effect. This should be of interest because al-
though the view of placebo as a conditioned response is
not new, previous analyses have remained at a descrip-
tive rather than an experimental level (see Suchman
and Ader 1992). As pointed out by Schiff (1982), since
the original observation of Pavlov (1927) that some
symptoms seen with an acute morphine injection could
be elicited by preinjection procedure alone, numerous
investigators demonstrated the classical conditioning of
morphine responses (see Lynch et al. 1976). In this re-
spect, hyperactivity and stereotyped behaviors induced
by dopamine agonists such as apomorphine, amphet-
amine and L-DOPA have also been conditioned in ro-
dents (Pickens and Crowder 1967; Tilson and Rech 1973;
Schiff et al. 1980; Schiff 1982; Hiroi and White 1989;
Carey 1992). However, in all of these studies the condi-
tioned stimulus was an injection procedure with signals
such as tone and/or specific environments. In our ex-
periments, mice were long-term treated, challenged
and observed for catalepsy in different rooms. In addi-
tion, no kind of signals were associated with the injec-
tion procedures. Thus, as far as we know, this is the first
study to show a classical conditioning of a response in-
duced by dopamine antagonists and a classical condi-
tioning of a dopaminergic agent response in which the
conditioned stimulus was injection procedure only. In
this respect, it should be acknowledged that the cata-
lepsy tests are presumably a sample observation of a
state produced by SCH 23390 (or neuroleptics). Thus,
the injection-procedure conditioning to the drug effects
observed after repeated treatment should also appear
in home-cage controls or should also be detected in
other behavioral models that are able to measure motor
activity. This is an interesting working hypothesis.
Dopamine systems of the brain have extensively
been implicated in mediating reward-related behavior
(Wise and Bozarth 1987; Wise and Rompre 1989; Di
Chiara 1995; Ikemoto et al. 1997). Within this context,
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the findings described in the present investigation seem
to be of special relevance as regards the hypothesis that
D1-like dopamine receptors are the final target from
which dopamine elicits rewarding effects (see Miller et
al. 1990). According to this hypothesis, the motor sig-
nals in the striatum which generate the cataleptic be-
havior induced by dopamine D1 antagonists would not
become linked by the reward signal to the sensory con-
ditions in which they habitually occur (the apparatus in
which the drug is given, or the circumstances associ-
ated with drug injection). As a consequence, the “re-
peated measures effect” on catalepsy behavior should
not be expected in animals treated with dopamine D1
antagonists (Miller et al. 1990). In marked opposition to
this premise, we demonstrated that mice treated chron-
ically with SCH 23390 not only showed a strong re-
peated measures effect in the catalepsy bar test, but also
presented a conditioned cataleptic response to the injec-
tion procedure alone. Although the conjecture that
dopamine D1 receptors are the “final common path-
way” for reward is supported by several other behav-
ioral measures to which dopamine is related (see Miller
et al. 1990), the present findings may provide new im-
petus for further characterization of the role of D1-like
dopamine receptors in the reward function.
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